Study To assess the safety and tolerability of AGEN1884 administered in combination with pembrolizumab as a first-line treatment of subjects with metastatic Non Small Cell Lung Cancer (NSCLC).
Phase 2
Recruiting
- Conditions
- on Small Cell Lung Cancer
- Registration Number
- ACTRN12617001061325
- Lead Sponsor
- Agenus Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 26
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method